Wednesday, July 8, 2026

pharma · Clostridium Difficile Infection · Clostridium Difficile Infection Recurrence · ACXP

Acurx Pharmaceuticals

Acurx Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Palatine, USA HQ
2003 Founded
9 Employees
Public company Type
ACXP · NYSE Ticker
Company details
Status
Public
HQ
Palatine, USA
Founded
2003
Employees
9
Programs
2
Drugs
1
Patents
28
Intelligence · Clinical Programs

Acurx Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Acurx Pharmaceuticals.

Acurx Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Ibezapolstat

    Acurx Pharmaceuticals

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial
  2. Ibezapolstat

    Acurx Pharmaceuticals

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Acurx Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.